Exicure, Inc.

Contributing Author

Recent Articles by Exicure, Inc.

Dec-08	Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting XCUR GlobeNewswire
Nov-07	Exicure, Inc. Reports Third Quarter 2025 Financial Results XCUR GlobeNewswire
Nov-03	New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting XCUR GlobeNewswire
Oct-06	Exicure Highlights Recent Achievements and Near-term Strategic Priorities XCUR GlobeNewswire